Esperion Therapeutics

$28.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.13 (+4.13%) Today

+$0.15 (+0.53%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ESPR and other stocks, options, and ETFs commission-free!

About ESPR

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI. The listed name for ESPR is Esperion Therapeutics, Inc. Common Stock.

CEO

Tim M. Mayleben

Employees

479

Headquarters

Ann Arbor, Michigan

Founded

1998

Market Cap

800.79M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

836.63K

High Today

$28.72

Low Today

$27.50

Open Price

$28.46

Volume

679.64K

52 Week High

$56.85

52 Week Low

$23.90

Analyst Ratings

55%

of 11 ratings

Buy

55%

Hold

27%

Sell

18%

ESPR Earnings

-$3.89

-$1.15

$1.58

$4.32

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

-$3.76 per share

Actual

-$3.89 per share

Replay Earnings Call